Exploring the intrathecal anti-inflammatory effect of cladribine and i
Exploring the intrathecal anti-inflammatory effect of cladribine and its relationship with clinical efficacy
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- MAVENCLAD 6CPR 10 mg
What it measured
Main measures
Decrement of CXCL13 expression level in NEDA group of patients with respect to no-NEDA group of patients at the end of the treatment.
Other measures (1)
-CXCL13 change in liquor.
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: -Treatment with Cladribine when provided by the local Authority (AOUI Verona), started at least 30 days before the enrolment. Exclusion: -Previous treatment with other DMT
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Verify whether a decrease of CSF levels of CXCL13 at the end of treatment (T24) with cladribine compared to the levels of CXCL13 before the treatment (T-3 -T-1) with cladribine is related to the achievement of “no evidence of disease activity” (NEDA).
Papers
Loading reviews and guidelines…
History
Started
Apr 2020